Granules India gains 4% on EIR from USFDA for Vizag facility
The said facility was inspected by USFDA in December 2016 and there were seven observations during the inspection.
Moneycontrol News
Shares of Granules India advanced 5 percent intraday Friday as it has received EIR from USFDA for its Vizag facility.
The United States Food & Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) for the company's OmniChem facility, which is a 50:50 JV company of Granules India and Ajinimoto OmniChem N. V. located at Vizag, Andhra Pradesh, India.
The said facility was inspected by USFDA in December 2016 and there were seven observations during the inspection.
This facility currently manufactures API intermediates.
At 13:29 hrs Granules India was quoting at Rs 120.10, up Rs 5.55, or 4.85 percent on the BSE.
The share touched its 52-week high Rs 157.00 and 52-week low Rs 91.45 on 18 May, 2017 and 09 November, 2016, respectively.
Posted by Rakesh Patil
Play in Progress 
